Regeneron Pharmaceuticals announced favorable findings from a two-year study of their experimental aflibercept 8 mg for the treatment of diabetic macular edema. The PHOTON study compared aflibercept 8 mg with 12- or 16-week dosage intervals to the authorized EYLEA (aflibercept) schedule of 8 weeks. Patients on the 12-week and 16-week aflibercept 8 mg regimens had an average of 9.5 and 7.8 injections after two years, compared to 13.8 injections for EYLEA. The majority of patients on aflibercept 8 mg were able to keep their prolonged dosage schedules, with 89% keeping at least a 12-week dosing plan and 84% keeping at least a 16-week dosing schedule. Aflibercept 8 mg was shown to be as safe as EYLEA, with no additional safety concerns.

To know more: About the original article click here.